Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05366829 · ClinicalTrials.gov registry record · Phase 2
Tislelizumab Consolidation After Liver-Directed Therapy for Hepatocellular Carcinoma
A Phase 2 study of Carcinoma, Hepatocellular and Liver Cell Carcinoma, sponsored by Rutgers, The State University of New Jersey.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
- 2
- Study locations
NCT05366829 is a Phase 2 study of Carcinoma, Hepatocellular and Liver Cell Carcinoma that is actively recruiting participants, run by Rutgers, The State University of New Jersey. The registered enrollment target is 35 participants, below the 611-participant average among 27 other Carcinoma, Hepatocellular trials with a reported enrollment target (94% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT05366829, a Phase 2 study of Carcinoma, Hepatocellular and Liver Cell Carcinoma, is actively recruiting participants, sponsored by Rutgers, The State University of New Jersey.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
- 2
- Study locations
Study Summary
The investigators hypothesize that the addition of Tislelizumab after definitive local therapy for locally advanced inoperable Hepatocellular carcinoma (HCC) will synergize with local therapy as well as treat micro metastatic disease and improve one year progression-free survival rates for participants and optimize local control.
Conditions Studied
Interventions
- DRUG Tislelizumab
Study Locations (2)
New Jersey
- Rutgers Cancer Institute of New Jersey - New Brunswick
New York
- Montefiore Medical Center - The Bronx
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2022-07-25 |
| Est. Completion | 2027-06-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05366829
The ClinicalTrials.gov registry entry for NCT05366829 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 611-participant average among 27 other Carcinoma, Hepatocellular trials with a reported enrollment target (94% lower). The listed sponsor is Rutgers, The State University of New Jersey, which has 413 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Carcinoma, Hepatocellular appearing as the primary indexed condition, and to 1 intervention - of which Tislelizumab is the first listed.
NCT05366829 reports 2 study locations spanning 2 distinct geographic areas - top geographies include New Jersey, New York.
Frequently Asked Questions
What is clinical trial NCT05366829 about?
NCT05366829 is a clinical study titled "Tislelizumab Consolidation After Liver-Directed Therapy for Hepatocellular Carcinoma". The investigators hypothesize that the addition of Tislelizumab after definitive local therapy for locally advanced inoperable Hepatocellular carcinoma (HCC) will synergize with local therapy as well as treat micro metastatic disease and improve one year progression-free survival rates for participa...
What is the current status of trial NCT05366829?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2022-07-25. Estimated completion is 2027-06-01.
What conditions does trial NCT05366829 study?
This clinical trial studies the following conditions: Carcinoma, Hepatocellular, Liver Cell Carcinoma.
What interventions are being tested in trial NCT05366829?
The interventions under investigation include: Tislelizumab (DRUG).
Who is sponsoring clinical trial NCT05366829?
This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05366829 being conducted?
This trial has 2 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Carcinoma, Hepatocellular
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)
COMPLETED · Phase 2
-
TRC105 for Liver Cancer That Has Not Responded to Sorafenib
COMPLETED · Phase 2
-
A Study of GC33 (RO5137382) in Patients With Advanced or Metastatic Hepatocellular Carcinoma
COMPLETED · Phase 2
-
Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC)
COMPLETED · Phase 2
-
90Y Transarterial Radioembolization Versus Microwave Ablation in Small Hepatocellular Carcinoma With Hypoalbuminemia
RECRUITING · NA
-
Characterizing Disease Biology, Treatment and Toxicity in Older Adults With Hepatocellular Carcinoma
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.